Genentech is having their analyst meeting with earnings/guidance announcement on Friday. With Avastin approved for Breast Cancer, this will prob lead to increase in guidance. Just wanted to let you know and see what you think
These are my thoughts: Friday: Earnings, Guidance, Analysts Earnings: Hit top end of earnings, or beat earnings Guidance: Guidance will be positive and upbeat with Avastin's approval Analysts: Upgrades from those who haven't already Combine these with potential talks about other drug trials and Avastin sales, and I say we should have a GREAT day. And just to sweeten the deal, Cramer talked about DNA tonight for like 10 minutes and he will get his watchers to buy, pushing the stock up hopefully up and up even BEFORE Friday. I got lots of March80Calls. What do you all think? David